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Abstract
Background: The amount of gene expression data in the public repositories, such as NCBI Gene
Expression Omnibus (GEO) has grown exponentially, and provides a gold mine for
bioinformaticians, but has not been easily accessible by biologists and clinicians.
Results: We developed an automated approach to annotate and analyze all GEO data sets,
including 1,515 GEO data sets from 231 microarray types across 42 species, and performed 12,658
group versus group comparisons of 24 GEO-specified types. We then built GeneChaser, a web
server that enables biologists and clinicians without bioinformatics skills to easily identify biological
and clinical conditions in which a gene or set of genes was differentially expressed. GeneChaser
displays these conditions in graphs, gives statistical comparisons, allows sort/filter functions and
provides access to the original studies.
We performed a single gene search for Nanog and a multiple gene search for Nanog, Oct4, Sox2 and
LIN28, confirmed their roles in embryonic stem cell development, identified several drugs that
regulate their expression, and suggested their potential roles in sex determination, abnormal sperm
morphology, malaria infection, and cancer.
Conclusion: We demonstrated that GeneChaser is a powerful tool to elucidate information on
function, transcriptional regulation, drug-response and clinical implications for genes of interest.
Background
The amount of gene expression data in the public reposi-
tories, such as NCBI Gene Expression Omnibus (GEO) [1]
has grown exponentially, and provides a gold mine for
bioinformaticians, but has not been easily accessible by
biologists and clinicians. Microarrays measure the expres-
sion of thousands of genes simultaneously, and have rev-
olutionized basic and clinical research by enabling the
unbiased discovery of sets of genes whose expression is
characteristic of a given cell type, treatment or disease
state. Since the advent of this technology more than a dec-
ade ago, we have accumulated the expression levels of
Published: 18 December 2008
BMC Bioinformatics 2008, 9:548 doi:10.1186/1471-2105-9-548
Received: 19 August 2008
Accepted: 18 December 2008
This article is available from: http://www.biomedcentral.com/1471-2105/9/548
© 2008 Chen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Bioinformatics 2008, 9:548 http://www.biomedcentral.com/1471-2105/9/548essentially all genes in the genomes for more than 100
species, across many tested biological conditions, such as
diseases, gene-knockouts, drug responses, genotype varia-
tions, and more. There is still a need for a bioinformatics
resource to analyze these data and enable biologists and
clinicians to easily identify all experimental conditions in
which a given gene or set of genes is differentially
expressed, which would be very useful in elucidating the
biological functions, transcriptional regulation, drug-
response and clinical implication of those genes.
Before 2001, microarray data could only be retrieved indi-
vidually from lab web sites. GEO was built in 2001 as a
first generation centralized repository of microarray data
to facilitate the submission, storage, and retrieval. A Euro-
pean counterpart, ArrayExpress [2], was later built by
European Bioinformatics Institute. These databases have
been tremendously successful, as evidenced by the expo-
nential increase of deposited data. As of this writing, GEO
contained 256,691 microarray samples from 9,988 exper-
iments across over 100 species using 5,134 types of micro-
arrays, summing over nine billion expression
measurements. Furthermore, the count of microarrays has
been doubling or tripling every year. GEO now contains
expression measurements for all human genes in 2,394
conditions, including 139 diseases. However, biologists
lacking bioinformatics skills have difficulties using and
interpreting the data in these repositories. As a result, a
second generation of microarray databases was designed
to select and analyze subsets of publicly-available micro-
arrays and display these using a user friendly interface. For
example, GNF SymAtlas [3] contains expression profiles
for most protein-coding genes in 79 human and 61
mouse tissues. The Connectivity Map [4] identifies expres-
sion profiles of different cell lines after perturbation by a
catalog of small molecule drugs. L2L [5] manually col-
lected 357 lists of genes that were differentially expressed
under different stimuli enabling the comparison with any
list of genes of interest to identify their underlying pat-
terns. Oncomine [6] contains the manually collected and
analyzed expression profiles of 40 cancer types from
25,447 microarray samples in 360 experiments. NextBio
[7] manually analyzed some data from GEO, ArrayEx-
press, and Stanford Microarray Database and delivered
expression profiles for a larger number of tissues, diseases,
and treatments. The creators of these databases performed
a handful of experiments or manually curated a subset of
experiments from public repositories, and delivered the
results for some types of conditions, such as tissue expres-
sion in SymAtlas, drug perturbation in connectivity map
and cancer profiling in Oncomine. Nextbio processed a
large number of experiments from multiple repositories,
but the data sets were still manually curated for only three
types of experimental conditions, such as tissue type, dis-
ease and treatments. Although very useful, these databases
are relatively restricted in their applications, and there is
still a need for a resource to quickly process whole data
sets from repositories for all types of conditions.
We have previously developed a fully automated tool
AILUN [8] that reannotates the complete data from GEO
for all types of arrays across all species. This paper
describes a web server, GENE CHAnge browSER (Gene-
Chaser[9]) that automatically reannotates and analyzes
all GEO data sets (GDS), performs all group versus group
comparisons, identifies all experimental conditions where
the expression levels of a gene or set of genes is signifi-
cantly changed, and displays them graphically with statis-
tical comparisons and sort/filter functions. It also
provides access to the raw data in the original studies. We
provide examples that show how well-known genes
involved in stem cell pluripotency can be used as search
criteria, yielding previously known and unknown condi-
tions that alter these genes.
Results
Microarray data analysis
We used AILUN [8] to parse and reannotate 1,515 GEO
data sets (GDS) spanning 231 microarray platforms
(GPL) and 42 species with the latest probe-gene annota-
tions. We performed all group versus group comparisons
within each GDS. For example, GDS2654, a study of age-
related neurological senescence in mice, was annotated
with 4 experimental variables, including disease state,
strain, tissue, and age. There were 2 groups in the disease
state, resulting in 1 comparison: accelerated aging versus
normal. There were 3 groups in strain, resulting in 3 com-
parisons: SAMP1 versus SAMP8, SAMP1 versus SAMP10,
and SAMP8 versus SAMP10. Similarly, we performed 1 tis-
sue comparison, hippocampus versus retina, and 1 age
comparison, 3 month versus 16 month. Comparisons
were constrained on groups with 3 or more samples. In
total, we performed 12,658 comparisons across 1,515
GDSs, involving 31,602 total microarrays.
For every comparison, we recorded all differentially
expressed genes and their corresponding q-values with a
false discovery threshold of 0.2 (q ≤ 0.2) using Signifi-
cance Analysis of Microarray (SAM) [10] in the siggenes
package of Bioconductor. In 5,457 of 12,658 compari-
sons, at least one gene was differentially expressed at a q-
value ≤ 0.05. On average, each comparison contained
1,857 differentially expressed genes and each gene was
differentially expressed in 54 comparisons and 17 GDSs.
A lot of diseases have been studied in multiple species. To
identify differentially expressed conditions across species,
we considered groups of orthologous genes as defined in
Entrez Homologene [11]. Of 45,205 ortholog groups in
Homologene, the expression of 37,998 groups was meas-
ured in one or more comparisons, of which 35,572Page 2 of 9
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showed differential expression in at least one comparison.
Each Homologene group was on average differentially
expressed in 233 comparisons and 71 GDSs.
GeneChaser
We then developed GeneChaser, a web server that identi-
fies and visualizes comparisons in which a gene or set of
genes was significantly differentially expressed. We imple-
mented two search functions, single gene search and multi-
ple gene search. Single gene search takes as input any gene
identifier, such as a gene symbol or Swissprot ID, and
returns comparisons relevant to the differential expres-
sion of that gene and optionally its orthologs. The under-
lying universal gene identifier table [8] contains 83
million identifiers for 3.6 million genes from 4578 spe-
cies, enabling us to recognize most gene identifiers, even
a university clone ID or IMAGE clone ID.
Single gene search
We performed a single gene search in all species for Nanog,
a key transcription factor necessary for pluripotency in
embryonic stem (ES) cells [12]. Nanog, or one of its
orthologs, was measured in 5,706 comparisons and was
differentially expressed in 217 of them (q ≤ 0.05, fold > 2)
(Additional File 1, [13]). The most significant change in
Nanog expression was 1000-fold upregulation in ES cells
compared to hematopoietic stem cells (q = 0.006,
GDS2718). Within the top 15 studies where Nanog was
up-regulated by more than 25 fold, all except two tissue
comparisons were studies of preimplantation embryonic
developments in different strains of mice. These studies
reveal continuously increased expression of Nanog as an
organism progressed from being an oocyte to having 1, 2,
and 8 cells, and finally to the blastocyst stage. The
increased expression is the most significant at 8-cell stage.
This clearly confirms a role for Nanog in ES cell develop-
ment, consistent with the current understanding of
embryonic development as well as recent experiments
with induced pluripotent cells [14].
To better understand the impact of different factors on
Nanog expression, we filtered the above comparisons by
comparison types. Currently, there are 24 GEO-specified
comparison types, including disease state, genotype/vari-
ation, strain, infection, development stage, age, time,
agent, dose, tissue, cell type, cell line, metabolism, stress,
growth protocol, protocol, gender, individual, isolate,
shock, species, specimen, temperature, and others.
Filtering revealed interesting connections between Nanog
expression and disease state, infection and drug-response.
Filtering by disease state comparison showed that Nanog
was significantly upregulated in abnormal sperm mor-
phology and significantly downregulated in malaria infec-
tion (Fig. 1, [15]). It was 20.2-fold upregulated in the
sperm cells from male with consistent and severe terato-
zoospermia, a condition in which less than 4 percent of
sperm cells are morphologically normal, compared to
controls (q < 0.0005, rank = 0.5%ile, GDS2697). It was
also significantly downregulated in the peripheral blood
mononuclear cells (PBMC) from malaria infected patients
compared to uninfected controls (fold = 4.5, rank =
3.3%ile, q < 0.0005) and presymptomatic infected
patients (fold = 3.4, rank = 7.7%ile, q < 0.0005)
(GDS2362). These studies suggest roles of Nanog in both
abnormal sperm morphology and malaria infection.
These findings have not been previously reported as only
a few selected genes were described in the original publi-
cations [16,17], which is common for most microarray
studies. Therefore, GeneChaser enabled the reuse of the
whole data set of deposited microarray studies, instead of
a few genes described in the publications.
As expected, Nanog was also significantly downregulated
in various types of cancer and progression in human stud-
ies (Fig. 1, [15]). It was 13.3-fold downregulated in pri-
mary malignant melanoma samples (q < 0.0005) and 2.2-
fold downregulated in benign skin nevi (q = 0.004) com-
pared to normal skin samples (GDS1375). It was also sig-
nificantly downregulated in metastatic prostate cancer
tumors compared to benign tumors (fold = 3.6, q = 0.022)
and clinically localized tumors (fold = 3.5, q = 0.024,
GDS1439). It was 3.4-fold downregulated in the plasma
cells from patients with plasma cell leukemia compared to
patients with premalignant conditions (q = 0.017,
GDS1067). The significant downregulation of Nanog in
multiple independent studies of various types of cancer
indicated a potential role in cancer and progression, con-
sistent with previous reports linking cancer to stem cell-
like phenotypes [18].
Filtering by agent comparisons showed that Nanog
expression was significantly affected by certain drugs
(Additional File 2, [19]). For example, it was 6.4-fold
upregulated in non-small cell lung cancer after treatment
with gemcitabine (q = 0.03, GDS2777). It was also 2.9-
fold downregulated in PBMC of malaria infected patients
after treatment with chloroquine (q = 0.003, GDS2362).
Its expression in ES cells was downregulated after treat-
ment with retinoic acid (RA), and upregulated after treat-
ment of dimethyl sulfoxide (DMSO) (GDS1823). These
drugs could potentially be used to regulate the expression
of Nanog for functional study.
Multiple gene search
NANOG, OCT4(Pou5f1), SOX2, and LIN28 were previ-
ously found to be sufficient to reprogram human somatic
cells to pluripotent stem cells that exhibit the essential
characteristics of embryonic stem (ES) cells [14]. We per-Page 3 of 9
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significantly differentially expressed in five mouse studies
(q ≤ 0.05) (Additional File 3, [20]). The most significant
change was that Nanog (fold = 1000, q = 0.006), Oct4
(fold = 333, q = 0.006), Sox2 (fold = 1000, q = 0.006) and
LIN28 (fold = 143, q = 0.006) were all significantly upreg-
ulated in ES cells compared to hematopoietic stem cells
(GDS2718). This confirmed their roles in ES cell develop-
ment.
An age comparison showed that Nanog (fold = 2.5, q =
0.006), Oct4 (fold = 3.2, q = 0.036), Sox2 (fold = 9.7, q =
0.013) and LIN28 (fold = 4.5, q = 0.006) were all down-
regulated in the gonadal somatic cells from mouse
embryo at 11.5 compared to 10.5 days post coitum
(GDS1724), which spans the critical period of male sex
determination. The significant downregulation of all four
critical ES cell factors suggested a potential role of ES cell
differentiation in sex determination, gonad differentia-
tion, and sexual dysgenesis syndromes, which had not
been described in the original publication [21].
A genotype/variation comparison showed that Nanog
(fold = 1.14, q = 0.01), Oct4 (fold = 1.1, q = 0.029), Sox2
Top nine disease state comparisons showing differential expression of NanogFigure 1
Top nine disease state comparisons showing differential expression of Nanog. A single gene search for Nanog 
showed that it was measured in 5706 experimental conditions, and differentially expressed in 19 disease states in human stud-
ies (fold > 2, q ≤ 0.05). Bar colors represent q-values, length represents fold change, and width represents rank percentile. 
Long, wide, red bars show increased significance. It was 20.2-fold upregulated in the sperm cells with abnormal morphology 
compared to controls. It was significantly downregulated in the PBMC from malaria infected patients compared to uninfected 
controls (fold = 4.5, q < 0.0005) and presymptomatic infected patients (fold = 3.4, q < 0.0005). It was also significantly down-
regulated in multiple independent cancer studies, including 13.3-fold downregulation in primary malignant melanoma samples, 
3.6-fold downregulation in metastatic prostate cancer tumors and 3.4-fold downregulation in the plasma cells from patients 
with plasma cell leukemia.
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were all downregulated in stearoyl-CoA desaturase 1
(Scd1) deficient mice (GDS1517). Considering they were
only 1.2-fold downregulated after the knockout of Oct4 in
mice (GDS1824), these changes are still significant. This
finding suggests that Scd1 might be an upstream regulator
of these four ES cell factors.
These four genes were also significantly differentially
expressed in 35 human studies (q ≤ 0.05) (Additional File
4, [22]). For example, Nanog (fold = 13.3, q < 0.0005),
Oct4 (fold = 3.8, q < 0.0005), Sox2 (fold = 1.5, q = 0.018)
and LIN28 (fold = 2.3, q = 0.033) were all significantly
downregulated in primary malignant melanoma samples
compared to normal skin samples (GDS1375).
To further investigate the role of ES cell factors in diseases,
we performed another multiple gene search on Nanog, Oct4
and Sox2 and found that they were all significantly upreg-
ulated in abnormal sperm morphology, and significantly
downregulated in malaria infection and cancer in human
studies (Fig. 2, [23]). Nanog (fold = 4.5, q < 0.0005), Oct4
(fold = 2.3, q < 0.0005) and Sox2 (fold = 3.0, q < 0.0005)
were all significantly downregulated in the PBMC from
malaria infected patients compared to controls
(GDS2362). The result indicates that key regulators of
pluripotency are down-regulated in the response to malar-
ial infection.
Discussion
We developed GeneChaser to automatically analyze all
GEO data sets (GDS), identify all experimental conditions
in which a gene or set of genes was differentially
expressed, and suggest biological functions, clinical impli-
cations, and regulators for genes of interest. We performed
a single gene search for Nanog and found its most signifi-
cant regulation is in embryonic stem (ES) cells compared
to hematopoietic stem cells. This is consistent with our
current understanding of Nanog in ES cell developments.
We further found its potential association with abnormal
sperm morphology, malaria infection and cancers. We
also found four drugs that regulate the expression of
Nanog, which could potentially be used for its functional
studies.
We also showed how a multiple gene search for Nanog,
Oct4, Sox2 and LIN28 confirms their most significant reg-
ulation in ES cells, and suggests their roles in the sex deter-
mination. We found that stearoyl-CoA desaturase 1
(Scd1) might be an upstream factor for all four ES factors.
We further found that Nanog, Oct4 and Sox2 were all sig-
nificantly upregulated in abnormal sperm morphology
and dowregulated in malaria infection and cancer, which
suggests a potential role of ES cell differentiation in these
diseases.
Second generation microarray databases, such as GNF
SymAtlas, Connectivity Map, L2L, Oncomine and Nextbio
rely on manual curation of data. While these tools are
extremely useful, they are also labor-intensive. With the
advent of an automatic microarray annotation tool
AILUN, GeneChaser analyzes all GEO data sets in a fully
automatic way. This frees users from the limitations of
manually curated data sets, and enables us to incorporate
new data faster and more easily. In addition, in contrast to
the small number of pre-established comparison types in
the older databases, GeneChaser allows us to take advan-
tage of all comparison types in GEO. As a result, we were
able to perform complete group versus group compari-
sons of all GEO data sets, including numerous compari-
sons the original authors did not perform. These
comparison types were also incorporated into Gene-
Chaser's filters which enable users to quickly identify spe-
cific experimental conditions of interest. Finally, we
designed color bars to represent output conditions that
enable easy visualization and comparison according to
different characteristics, including q-value, fold change,
and rank percentile.
Of the second generation microarray databases, Nextbio
contains gene profiling for a very large number of condi-
tions. GeneChaser is different from Nextbio by offering a
multiple gene search function, which we have shown here
to be a powerful tool to identify conditions, such as the
role of ES cell factors in sex determination, abnormal
sperm morphology, malaria infection and cancer. Gene-
Chaser also analyzed all 24 GEO-specified types of exper-
imental conditions, while Nextbio only manually curated
three types of experimental conditions. For example, a
search of Nanog on Nextbio returned 210 conditions,
while a single gene search of Nanog in GeneChaser
returned 407 conditions (q ≤ 0.05). GeneChaser was also
different from Nextbio by providing statistical compari-
sons with multi-test correction (q-value) and informative
color bars to compare different conditions. Most impor-
tantly, the construction and update of GeneChaser are
fully automatic, which enabled us to incorporate the data
faster and easier. We are committing to refresh with the
latest gene profiling database and update GeneChaser
four times per year.
Conclusion
In summary, GeneChaser analyzed all GEO data sets in an
automated way to quickly deliver gene expression profiles
under 12,658 experimental conditions across all species
to the hands of biologists and clinicians without bioinfor-
matics skills. We performed a single gene search for Nanog
and a multiple gene search for Nanog, Oct4, Sox2 and LIN28,
confirmed their roles in embryonic stem (ES) cell devel-
opment, identified several drugs that regulate their expres-
sion, and suggested potential roles of ES cell factors in sexPage 5 of 9
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Comparisons resulting differential expression of Nanog, Oct4 and Sox2Figure 2
Comparisons resulting differential expression of Nanog, Oct4 and Sox2. A multiple gene search for Nanog, Oct4 
(pou5f1), and Sox2 in human studies showed that they were all significantly upregulated in abnormal sperm morphology, and 
downregulated in malaria infection and cancer. Nanog (fold = 20.2, q < 0.0005), Oct4 (fold = 2.0, q < 0.0005) and Sox2 (fold = 
2.3, q < 0.0005) were all significantly upregulated in the abnormal sperm morphology compared to controls. Nanog (fold = 4.5, 
q < 0.0005), Oct4 (fold = 2.3, q < 0.0005) and Sox2 (fold = 3.0, q < 0.0005) were all significantly downregulated in the PBMC 
from malaria infected patients compared to controls. They were also significantly downregulated in various types of cancers, 
such as plasma cell leukemia and malignant melanoma. Clicking the average q-values and fold changes opens values for individual 
genes.
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iso la t ion  an d  leu k ocy t e 
RNA p u r i f i ca t ion :  
com p ar ison  o f  m et h od s
 PAXgene vs. buf fy  c oat prot oc ol 4 .2  0 .0  0 .0 1 4 3  
9 W h o le b lood  RNA 
iso la t ion  an d  leu k ocy t e 
RNA p u r i f i ca t ion :  
com p ar ison  o f  m et h od s
 w hole b lood vs. 
leuk oc yt e
t issue 4 .2  0 .0  0 .0 1 4 3  
10 Pr esy m p t om at ic an d  
sy m p t om at ic m alar ia :  
p er ip h er a l  b lood  
m on on u clear  ce l l s
 un in fec t ed vs. 
sym pt om at ic , nat ura l ly  
ac qui red
disease 
s t a t e
3 .3  
Sy m b o l Fo ld
NANOG 4 .4 8 4 3
POU5 F1 2 .3 4 7 4 2
SOX2 3 .0 3 0 3
0 .0  0 .0 0 0 0  
Sy m b o l q  v a lu e
NANOG 0
POU5 F1 0
SOX2 0
11 Pr esy m p t om at ic an d  
sy m p t om at ic m alar ia :  
p er ip h er a l  b lood  
m on on u clear  ce l l s
 un in fec t ed basel ine vs. 
ac ut e in fec t ion
in fec t ion 3 .3  0 .0  0 .0 0 0 0  
12 Plasm a cel l  d y scr asias  m onoc lonal  
gam m opat hy of  
undet erm ined 
s ign i f ic anc e vs. p lasm a 
c e l l  leuk em ia
disease 
s t a t e
2 .7  
Sy m b o l Fo ld
NANOG 3 .4 1 2 9 7
POU5 F1 2 .2 5 7 3 4
SOX2 2 .3 9 8 0 8
0 .0  0 .0 2 7 3  
Sy m b o l q  v a lu e
NANOG 0 .0 1 7
POU5 F1 0 .0 4 5
SOX2 0 .0 2
13 Var iou s n o r m al  p u r e cel l  
cu l t u r es
 ep i t he l ia l  vs. 
endot hel ia l
c e l l  t ype 2 .6  0 .0  0 .0 0 4 7  
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infection, and cancer. With the expected doubling or tri-
pling data accumulation in GEO, GeneChaser will quickly
expand to a complete spectrum of biological and clinical
conditions to elucidate biological functions, clinical
implications, transcriptional regulators, and drug
response for novel genes.
Methods
Microarray Data Analysis
Gene Expression Omnibus (GEO) is a centralized reposi-
tory of gene expression data. Each array is recorded as a
GEO sample (GSM). A group of related GSM from one
study was linked together as a GEO series (GSE) according
to the user submission. A collection of biologically and
statistically comparable GSM from a study was then
curated by GEO staff to form a GEO data set (GDS). All
samples within a GDS were measured on the same plat-
form with the same background processing and normali-
zation, and their values were directly comparable. Some
GSM were not included in the GDS. GEO staff categorized
each GDS into subsets and annotated them with one of
the 24 types.
We downloaded and parsed all SOFT files of GDS into a
relational database using AILUN [8]. The types of expres-
sion values were recognized from "dataset_value_type" in
the GDS SOFT files and transformed into log2 values as
needed. We wrote an R script to perform all possible sub-
set-versus-subset comparisons in each GEO-defined type
in every GDS, ignoring subsets with less than 3 samples.
For every comparison, we identified all differentially
expressed probes with q-value ≤ 0.2 using the SAM func-
tion [10] in siggenes package of Bioconductor. We used
AILUN [8] to translate differentially expressed probe IDs
to Entrez Gene IDs. All q-values and fold changes were
recorded. Because the number of differentially expressed
genes varied among comparisons, a rank percentile was
calculated for each gene based on its fold change among
all changing genes (q ≤ 0.2) in each comparison.
In the original platform annotation files released from
GEO, some probes were not annotated with any Entrez
Gene ID, such as probe 575 in GPL5. An annotation of
"FBgn0036403" was listed with a column header of
"Platform_CLONEID". AILUN automatically recognized
it as a FLYBASE ID and related it to an Entrez Gene ID
39556 using our universal gene identifier table, which
contains 83 million identifiers for 3.6 million genes from
4578 species[8]. AILUN also removed all probes that were
annotated with multiple Entrez Gene IDs to ensure a
high-quality annotation.
We saved all performed comparisons in a table in MySQL
database, which contains 12,658 comparisons. All differ-
entially expressed genes along with their q values, fold
changes, and rank percentiles were saved in a table, which
contains 28 million entries. The whole process from data
downloads, platform annotation, and gene identification,
to database development was fully automated.
Single gene search
GeneChaser directly retrieves qualified comparisons from
our tables in MySQL. In single gene search, we first searched
for a gene input in the official gene symbols in Entrez
Gene and Homologene. If failed, we searched for it in our
universal gene identifier table [8] to identify matching
Entrez Gene IDs and Homologene group ID. When mul-
tiple Entrez Gene and Homologene IDs matched, they
were all displayed with description for selection. Clicking
an Entrez Gene ID returned comparisons where a gene
was differentially expressed, while clicking a Homologene
group ID returned comparisons where at least one gene in
the group was differentially expressed.
Matched comparisons were displayed in color bars, which
were created with the HTML div tag, with length = min
(fold change, 10) × 50, width = ((1 - rank percentile) +
0.05) × 50 and color for q-value. Redder bars indicated
better q-value. The fold change was calculated as the
expression level change of subset A/B, which was listed
under the color bar. When fold change was less than 1, we
exchanged subset A and B to ensure that fold change was
shown as larger than 1. Results were displayed as thresh-
olds filtered by q-value, fold change, title keyword, and
comparison types. Displayed graphic results could be
saved as a high-quality image, which was created using
PHP's GD library (bundled 2.0.28 compatible).
Multiple gene search
Similar with single gene search, we first identified corre-
sponding Entrez Gene IDs for two input gene lists.
Because the majority of individual microarray studies
measure gene expression in a single species, we restricted
all input genes to be in the same species, which greatly
reduced the number of matching Entrez Gene IDs. If mul-
tiple species or genes were matched, we displayed all with
description for user selection.
We then retrieved all comparisons in which genes on the
first list were upregulated and those on the second list
were downregulated using user-defined q-value cutoffs.
All comparisons were saved into a temporary table con-
taining fold changes and q-values for both individual
genes and the average change, which was then used to cre-
ate a HTML table for display.
User guide
GeneChaser is a gene-specific search tool across all exper-
imental conditions in GEO. In single gene search, the input
is a gene identifier, such as a gene symbol. For example, a
search for "Nanog" returns a list of matching IDs fromPage 7 of 9
(page number not for citation purposes)
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ID returns experimental conditions in a single species,
while clicking a Homologene ID returns experimental
conditions in all species. For example, Nanog was meas-
ured in 5,706 comparisons, and differentially expressed in
217 (q ≤ 0.05, fold > 2) [13]. Each row in the output table
lists Nanog expression in an identified comparison, and
includes the rank of comparison, species, study title, a
color bar representing the significance of the comparison,
comparison type, fold change, rank percentile among all
changing genes with q-value ≤ 0.2 in the comparison, and
q-value. The color represents the q-value, with redder
colors indicating higher significance. Bar length represents
fold change with longer lengths for larger changes. Bar
width represents rank percentile with greater widths for
higher percentiles. Clicking on the title opens the original
study with the raw GEO data. Clicking on the colored bar
opens the original expression values for the probe in GEO,
including present/absent calls for Affymetrix arrays. The
two groups under comparison are listed under the color
bar. For example, the first row indicates that Nanog was
1000-fold upregulated (q = 0.006, rank = 0.2%ile) in
embryonic stem cell compared to hematopoietic stem cell
in mice [13]. More detailed description is available by
clicking Legends (top right).
Results can be threshold filtered by q-value, fold, rank per-
centile, and comparison types. Comparison types are
defined by GEO. The comparison type filter is convenient
for quickly identifying conditions of interest. For example,
disease state lists all diseases where Nanog was differen-
tially expressed. Genotype/variation and strain return muta-
tion and knockout studies. Agent suggests drugs for
regulating Nanog expression. Other frequently used com-
parison types include infection, protocol, tissue, cell type, cell
line, development, and age. User can also use keywords to
filter study titles. Results are initially sorted by q-values,
but can be re-sorted by fold change, title, rank percentile,
and species. Changes to filter thresholds and sort selec-
tions are retained if a user selects Start Over for a new
search. Results can be displayed graphically or as text in
Display Results (top left). Graphical results can be saved in
a high quality PNG file using Create Image. Textual results
can be downloaded as a tabbed text file for detailed anal-
ysis. A permanent link can be created by Link to this page,
which can be forwarded to collaborators.
Similar to single gene search, multiple gene search takes a list
of up- and downregulated genes as input and displays dif-
ferentially expressed comparisons with average fold
changes and q-values. Clicking the average values opens
individual values for each input gene.
Availability and requirements
Project name: GeneChaser
Project homepage: http://genechaser.stanford.edu
Operating systems: Platform independent
Programming languages: R and PHP
Other requirements: Web browser (supporting JavaS-
cript)
Any restrictions to use by non-academics: License
needed
Abbreviations
ES cell: Embryonic Stem cell; GEO: Gene Expression
Omnibus; GDS: GEO Data Set; GPL: GEO Platform; GSE:
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Mononuclear Cells; SAM: Significance Analysis of Micro-
array.
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Additional file 1
Top conditions in which Nanog was significantly differentially 
expressed. A single gene search result shows the top 12 biological and clin-
ical conditions in which Nanog, or one of its orthologs, was differentially 
expressed (q ≤ 0.05, fold > 2).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-548-S1.pdf]
Additional file 2
Agent comparisons showing differential expression of Nanog. A single 
gene search result shows that Nanog, or one of its orthologs, was differen-
tially expressed after drug treatments in four studies (q ≤ 0.05, fold > 2).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-548-S2.pdf]
Additional file 3
Mouse studies showing differential expression of Nanog, Oct4, Sox2, 
and Lin28. A multiple gene search result shows that Nanog, Oct4, Sox2, 
and Lin28 were differentially expressed in five mouse studies (q ≤ 0.05).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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